Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
September 24, 2024
Loading feed metadata...
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet
Sign up